Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) (vol 43, pg 17, 2020)

被引：1
|
作者：
Patek, Taylor M. [1 ,2 ]
Teng, Chengwen [1 ,2 ]
Kennedy, Kaitlin E. [1 ,2 ]
Alvarez, Carlos A. [3 ]
Frei, Christopher R. [1 ,2 ,4 ,5 ]
机构：
[1] Univ Texas Austin, Pharmacotherapy Div, Coll Pharm, San Antonio, TX USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, Long Sch Med, 7703 Floyd Curl Dr,MSC-6220, San Antonio, TX 78229 USA
[3] Texas Tech Univ, Hlth Sci Ctr, Div Clin Translat Res, Hodge Sch Pharm, Dallas, TX USA
[4] South Texas Vet Hlth Care Syst, San Antonio, TX USA
[5] Univ Hlth Syst, San Antonio, TX USA
来源：
DRUG SAFETY | 2020年 / 43卷 / 08期
关键词：
D O I：
10.1007/s40264-020-00971-y
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
In the original publication of the article, the second sentence in the figure 2 caption should read as below:
引用
收藏
页码：825 / 825
页数：1
相关论文
共 50 条
  • [41] Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
    Tong, Lihua
    Yuan, Yanling
    He, Wanming
    Yang, Wen
    Pan, Xingxi
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [42] Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
    Shi, Alan
    Nguyen, Harold
    Kuo, C. Benson
    Beringer, Paul M.
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (03) : 566 - 572
  • [43] Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Teng, Chengwen
    Walter, Elizabeth A.
    Gaspar, Daryl Kevin S.
    Obodozie-Ofoegbu, Obiageri O.
    Frei, Christopher R.
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (07): : 1018 - 1022
  • [44] A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
    Tang, Linlin
    Sun, Cuicui
    Liu, Wenshan
    Wu, Haiyan
    Ding, Chuanhua
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] Pharmacovigilance study of the association between dipeptidyl peptidase–4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)
    Katsuhiro Ohyama
    Junichiro Shindo
    Tomohiro Takahashi
    Hironori Takeuchi
    Yusuke Hori
    Scientific Reports, 12
  • [46] Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
    Hong, Yifan
    Cheng, Kebin
    Qu, Han
    Wang, Yuting
    Wang, Yuanyuan
    Fan, Guorong
    Wu, Zhenghua
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2024, 10 (01):
  • [47] Voriconazole-induced central nervous system toxicity: a pharmacovigilance study based on FDA adverse event reporting system (FAERS) database
    Yun, Juping
    Wang, Zihe
    Liu, Wei
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (10) : 1309 - 1316
  • [48] Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Zhang, Chunyan
    Ren, Xiaolei
    Huang, Jing
    Huang, Lin
    Zhang, Xiaohong
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [49] Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)
    Wu, Tingxi
    Shi, Yanfeng
    Zhu, Bin
    Li, Dandan
    Li, Zhe
    Zhao, Zhigang
    Zhang, Yang
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (03) : 313 - 321
  • [50] Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
    Mao, KaiLi
    Chen, Ping
    Sun, HuaYu
    Zhong, SongYang
    Zheng, HongLiang
    Xu, LuYao
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345